Overview
INMB market data
Price History
INMB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.86 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.88 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -19,478.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.09 – $2.61 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $58.6M · P/B 1.76 · P/S 1,171.21.
Company News
INmune Bio Q2 EPS $(0.05) Beats $(0.21) EstimateBenzinga · Aug 6, 2026, 8:01 PM
8-K filing — Inmune Bio, Inc. (INMB)SEC EDGAR · Jul 31, 2026, 8:06 PM
INmune Bio Reaches Manufacturing Milestone with First Commercial-Ready CORDStrom Umbilical Cord Tissue Processed At CGT Catapult In Partnership With Anthony Nolan Cord Blood BankBenzinga · Jul 20, 2026, 11:17 AM
INmune Announces Publication Of Peer-Reviewed Study In The Journal Of Neurotrauma On Traumatic Brain Injury And Alzheimer’s; Treatment With Its Lead Neuroinflammation Candidate XPro1595 Prevented Injury-Induced Rise In Amyloid PathologyBenzinga · Jul 15, 2026, 11:22 AM
INmune Bio To Present New Imaging Data From Phase 2 Study Of XPro In Patients With Early Alzheimer’s Disease At AAICBenzinga · Jul 9, 2026, 11:10 AM
INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTOBenzinga · Jul 1, 2026, 11:15 AM
The UK Medicines & Healthcare Products Regulatory Agency Approves The Pediatric Investigation Plan For INmune Bio's Ebstrocel For Recessive Dystrophic Epidermolysis BullosaBenzinga · Jun 25, 2026, 11:20 AM
INmune Bio Receives Official Accepted Meeting Minutes From Recent Pre-MAA Scientific Advice Meeting With UK's MHRA For CORDStromBenzinga · Jun 23, 2026, 12:15 PM
INmune Bio Announces Results From Exploratory Chi-Separation MRI Imaging Analyses From MINDFuL Phase 2 Clinical Trial Of XPro In Patients With Early Alzheimer's DiseaseBenzinga · Jun 2, 2026, 12:16 PM
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's TrialGlobenewswire Inc · Jun 2, 2026, 12:15 PM